Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene

Clinica Chimica Acta

Volumn 368, Issue 1-2, 2006, Pages 149-154

  Pérez Méndez, Oscar ^a   Duhal, Nathalie ^b   Lacroix, Brigitte ^b   Bonte, Jean Paul ^b   Fruchart, Jean Charles ^a,b   Luc, Gérald ^a,b  

^a INSTITUT PASTEUR DE LILLE   (France)

^b UNIV LILLE   (France)

Author keywords

Apo AI; Apo AII; Apolipoprotein turnover; HDL; Lipoprotein lipase; Stable isotope

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; APOLIPOPROTEINS B; FEMALE; HETEROZYGOTE; HUMANS; KINETICS; LIPOPROTEIN LIPASE; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; MUTATION;

EID: 33646829137     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2005.12.038     Document Type: Article

References (47)

1. Assmann G., Schulte H., von Eckardstein A., and Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 (1996) S11-S20
2. Schaefer E.J., Lamon-Fava S., Ordovas J.M., et al. Factors associated with low and elevated plasma high-density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 35 (1994) 871-882
3. Wilson P.W.F., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
4. Bloomfield-Rubins H., Davenport J., Babikian V., et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103 (2001) 2828-2833
5. Patsch J.R., Prasad S., Gotto A.M., and Patsch W. High density lipoprotein2; relationship of the plasma level of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoproteinlipase and hepatic lipase. J Clin Invest 80 (1987) 341-347
6. Kekki M. Lipoprotein lipase action in determining plasma high density lipoprotein cholesterol level in adult normolipaemics. Atherosclerosis 37 (1980) 143-150
7. Kuusi T., Ehnholm C., Viikari J., et al. Postheparin plasma lipoprotein and hepatic lipase are determinants of hypo- and hyperalphalipoproteinemia. J Lipid Res 30 (1989) 1117-1126
8. Goldberg I.J., Blaner W.S., Vanni T.M., Moukides M., and Ramakrishnan R. Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoproteins metabolism. Studies in normal and lipoprotein lipase-inhibited monkeys. J Clin Invest 86 (1990) 463-473
9. Brinton E.A., Eisenberg S., and Breslow J.L. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 87 (1991) 536-544
10. Schaefer E.J., Zech L.A., Jenkins L.L., et al. Human apolipoprotein A-I and A-II metabolism. J Lipid Res 23 (1982) 850-862
11. Pietzsch J., Julius U., Nitzsche S., and Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 47 (1998) 1928-1934
12. Reilly M.P., Foulkes A.S., Wolfe M.L., and Rader D.J. Higher-order lipase gene association with plasma triglycerides. J Lipid Res 46 (2005) 1914-1922
13. Magill P., Rao S.N., Miller N.E., et al. Relationships between the metabolism of high-density and very-low-density lipoproteins in man: studies of apolipoprotein kinetics and adipose tissue lipoprotein lipase activity. Eur J Clin Invest 12 (1982) 113-120
14. Goldberg I.J., Le N.A., Ginsberg H.N., Krauss R.M., and Lindgren F.T. Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey. J Clin Invest 81 (1988) 561-568
15. Pacy P.J., Mitropoulos K.A., Venkatesan S., Watts G.F., Reeves B.E., and Halliday D. Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase. Atherosclerosis 103 (1993) 231-243
16. Frenais R., Nazih H., Ouguerram K., et al. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus. J Clin Endocrinol Metab 86 (2001) 1962-1967
17. Huesca-Gómez C., Franco M., Luc G., et al. Chronic hypothyroidism induces abnormal structure of high-density lipoproteins and impaired kinetics of apolipoprotein A-I in the rat. Metabolism 51 (2002) 443-450
18. Elkhalil L., Majd Z., Bakir R., et al. Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. Metabolism 46 (1997) 474-483
19. Ikewaki K., Rader D.J., Sakamoto T., et al. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 92 (1993) 1650-1658
20. Carreón-Torres E., Juárez-Meavepeña M., Cardoso-Saldaña G., et al. Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit. Atherosclerosis 181 (2005) 233-240
21. Huesca C., Luc G., Duhal N., Lacroix B., Fruchart J., and Perez-Mendez O. Ciprofibrate increases synthesis and catabolism of HDL apo AI and AII in patients with hypertriglyceridemia. Atheroscler suppl 5 (2004) 64
22. Taskinen M.R., Nikkila E.A., Kuusi T., and Harno K. Lipoprotein lipase activity and serum lipoproteins in untreated type II (insulin-independent) diabetes associated with obesity. Diabetologia 22 (1982) 46-50
23. Agardh C.D., Sartor G., and Nilsson-Ehle P. Plasma high density lipoproteins and lipolytic enzyme activities in diabetic patients. Acta Med Scand 213 (1983) 123-128
24. Pfeifer M.A., Brunzell J.D., Best J.D., Judzewitsc R.G., Halter J.B., and Porte Jr. D. The response of plasma triglyceride, cholesterol, and lipoprotein lipase to treatment in non insulin-dependent diabetic subjects without familial hypertriglyceridemia. Diabetes 32 (1983) 525-531
25. Taskinen M.R. Lipoprotein lipase in diabetes. Diabetes Metab Rev 3 (1987) 551-570
26. Frenais R., Ouguerram K., Maugeais C., et al. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia 40 (1997) 578-583
27. Hata A., Emi M., Luc G., et al. Compound heterozygote for lipoprotein lipase deficiency: Ser-Thr244 and transition in 3′ splice site of intron 2 (AG-AA) in the lipoprotein lipase gene. Am J Hum Genet 47 (1990) 721-726
28. Tenenbaum D., Gambert P., Fischbach M., d'Athis P., Nivelon J.L., and Lallemant C. Alterations of serum high-density lipoproteins and hepatic lipase activity in congenital hypothyroidism. Biol Neonate 54 (1988) 241-245
29. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
30. Cohn J.S., Wagner D.A., Cohn S.D., Millar J.S., and Schaefer E.J. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 85 (1990) 804-811
31. Perez-Mendez O., Bruckert E., Franceschini G., et al. Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. Atherosclerosis 148 (2000) 317-325
32. Cobelli C., Toffolo G., and Foster D.M. Tracer to tracee ratio for analysis of stable tracer data: link with radioactive kinetic formalism. Am J Physiol 262 (1992) E968-E975
33. Reeds P.J., Hachey D.L., Patterson B.W., Motil K.J., and Klein P.D. VLDL apolipoprotein B-100, a potential indicator of the isotopic labeling of the hepatic protein synthetic precursor pool in humans: studies with multiple stable isotopically labeled amino acids. J Nutr 122 (1992) 457-466
34. Emmerich J., Beg O.U., Peterson J., et al. Human lipoprotein lipase. Analysis of the catalytic triad by site-directed mutagenesis of Ser-132, Asp-156, and His-241. J Biol Chem 267 6 (Feb 25 1992) 4161-4165
35. Dugi K.A., Dichek H.L., Talley G.D., Brewer Jr. H.B., and Santamarina-Fojo S. Human lipoprotein lipase: the loop covering the catalytic site is essential for interaction with lipid substrates. J Biol Chem 267 (1992) 25086-25091
36. Brzozowski A.M., Derewenda U., Derewenda Z.S., et al. A model for interfacial activation in lipases from the structure of a fungal lipase-inhibitor complex. Nature 351 (1991) 491-494
37. Melchior G.W., Castle C.K., Vidmar T.J., Polites H.G., and Marotti K.R. Apo A-I metabolism in cynomolgus monkeys: male-female differences. Biochim Biophys Acta 1043 (1990) 97-105
38. Ooi E.M., Watts G.F., Farvid M.S., et al. High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res 13 (2005) 1008-1016
39. Evans V., and Kastelein J.J. Lipoprotein lipase deficiency-rare or common?. Cardiovasc Drugs Ther 16 (2002) 283-287
40. Henderson H.E., Kastelein J.J., Zwinderman A.H., et al. Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. J Lipid Res 40 (1999) 735-743
41. Rashid S., Trinh D.K., Uffelman K.D., Cohn J.S., Rader D.J., and Lewis G.F. Expression of human hepatic lipase in the rabbit model preferentially enhances the clearance of triglyceride-enriched versus native high-density lipoprotein apolipoprotein A-I. Circulation 107 (2003) 3066-3072
42. Golay A., Zech L., Shi M.Z., Chiou Y.A., Reaven G.M., and Chen Y.D. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab 65 (1987) 512-518
43. von Eynatten M., Schneider J.G., Humpert P.M., et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 27 (2004) 2925-2929
44. Garvey W.T., Kwon S., Zheng D., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003) 453-462
45. Goff Jr. D.C., D'Agostino Jr. R.B., Haffner S.M., and Otvos J.D. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 54 (2005) 264-270
46. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
47. Brites F., Verona J., Fernandez K., et al. HDL metabolic activities in a boy with lipoprotein lipase deficiency and his family. Eur J Clin Invest 34 (2004) 467-474